Home
About Us
We are a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in the areas of immunology, immuno-oncology and rare disease.
Our Approach
Our highly targeted clinical-stage therapeutics are founded on a strong scientific and clinical rationale that may enable accelerated clinical development and increased probability of clinical and regulatory success.
Our Pipeline
We are rapidly advancing a rich pipeline with the potential for broad clinical utility across Immunology, Immuno-oncology, and Rare Genetic Diseases.
Differentiating Attributes of Our Programs
- Novel mechanisms offering potential as first-in-class medications
- First available therapy and/or substantial improvement over existing therapies for serious diseases
- Targeted mechanisms of action with the potential for a favorable benefit-risk profile
- Candidates for accelerated clinical development and regulatory pathways
- Identified biomarkers and/or published clinical proof of concept increase the probability regulatory approval
- Associated biomarkers offer the potential for better patient identification and higher response rates
Recent News
Oct 13, 2021 7:00 am
Avalo to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
Sep 20, 2021 7:00 am
Avalo to Present at the 2021 Cantor Virtual Global Healthcare Conference
